Sector Focus/Pharma

////Sector Focus/Pharma

India: The world’s friendly drug supplier

2018-08-07T08:04:05+00:00February 9th, 2017|2017/2018, February 2017, Sector Focus/Pharma, Year|

The Indian pharmaceutical industry is holding on to a sliver of hope that it could become the supplier of choice for the US market. Indian IT sector CEOs aren’t the only ones weighing every word uttered by US President Donald Trump for nuances and burning the midnight oil wondering how to maintain their lead in their largest market. IT’s less glamorous but equally successful knowledge sector cousin, the Indian pharmaceuticals industry, is also worried about how the new US administration’s [...]

Affordable bio-pharma innovation that is Made in India

2018-08-06T13:39:21+00:00February 9th, 2017|2017/2018, February 2017, Sector Focus/Pharma, Year|

Kiran Mazumdar-Shaw is a consistent presence on definitive global lists as one of the world’s most powerful women. As the Chairman and Managing Director of Biocon Limited, she is a trendsetter in the field of biotechnology in India. Here she takes time out for ‘India Global Business’ to give us an insight into her entrepreneurial drive and India’s own biotech journey. How has India's biotech sector grown since you entered as a pioneer in the field? The Indian biotech industry [...]

Pharma sector makes its mark on the world

2020-03-26T07:13:57+00:00February 9th, 2017|2017/2018, February 2017, Sector Focus/Pharma, Year|

Some of India’s leading pharmaceutical majors made their mark with acquisitions in recent months.

Aurobindo Pharma buys Portugal firm

Aurobindo PharmaceuticalsAurobindo Pharma has announced the acquisition of Portugal’s Generis Farmaceutica SA.

The Hyderabad-based company said a definitive agreement was signed by its step-down subsidiary, Agile Pharma, Netherlands. The acquisition will be from Magnum Capital Partners for an all-cash deal, the company said.

It will include a manufacturing facility in Amadora, Portugal, which has the capacity to produce 1.2 billion tablets or capsules annually. After the acquisition, the Aurobindo Group will be the largest in the generic pharmaceutical market in Portugal, with a portfolio of 271 generic products.

Generis has a wide portfolio of products, with a major share in therapeutic areas such as cardiovascular, central nervous system, anti-infective, and the genitourinary system.

Aurobindo expects to complete the deal by next month, after the Portuguese Competition authorities clear the deal.